Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrineNIWA, T; SATO, R; YABUSAKI, Y et al.Xenobiotica (London. Print). 1999, Vol 29, Num 2, pp 187-193, issn 0049-8254Article

A polymorphism in the CYP17 gene increases the risk of breast cancerFEIGELSON, H. S; COETZEE, G. A; KOLONEL, L. N et al.Cancer research (Baltimore). 1997, Vol 57, Num 6, pp 1063-1065, issn 0008-5472Article

Inhibition of human hepatic cytochrome P450s and steroidogenic CYP17 by nonylphenolNIWA, Toshiro; MAEKAWA, Yumi; FUJIMOTO, Megumi et al.Biological & pharmaceutical bulletin. 2002, Vol 25, Num 2, pp 235-238, issn 0918-6158Article

The genetics, pathophysiology, and management of human deficiencies of P450c17AUCHUS, Richard J.Endocrinology and metabolism clinics of North America. 2001, Vol 30, Num 1, issn 0889-8529, vii,101-119 [20 p.]Article

17α-Hydroxylase/17,20-lyase deficiency as a model to study enzymatic activity regulation : Role of phosphorylationBIASON-LAUBER, A; KEMPKEN, B; WERDER, E et al.The Journal of clinical endocrinology and metabolism. 2000, Vol 85, Num 3, pp 1226-1231, issn 0021-972XArticle

The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysisZHENG YE; PARRY, James M.Mutagenesis. 2002, Vol 17, Num 2, pp 119-126, issn 0267-8357Article

Genetic aspects of epitestosterone formation and androgen disposition : influence of polymorphisms in CYP17 and UGT2B enzymesSCHULZE, Jenny Jakobsson; LORENTZON, Mattias; OHLSSON, Claes et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 6, pp 477-485, issn 1744-6872, 9 p.Article

Prostate cancer associated with CYP17 genotypeWADELIUS, M; ANDERSSON, S.-O; JOHANSSON, J.-E et al.Pharmacogenetics (London). 1999, Vol 9, Num 5, pp 635-639, issn 0960-314XArticle

COUP-TFI expression in human adrenocortical adenomas : Possible role in steroidogenesisSHIBATA, H; ANDO, T; SUZUKI, T et al.The Journal of clinical endocrinology and metabolism. 1998, Vol 83, Num 12, pp 4520-4523, issn 0021-972XArticle

Metabolism and interaction of bisphenol A in human hepatic cytochrome P450 and steroidogenic CYP17NIWA, Toshiro; FUJIMOTO, Megumi; KISHIMOTO, Kae et al.Biological & pharmaceutical bulletin. 2001, Vol 24, Num 9, pp 1064-1067, issn 0918-6158Article

The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancerHAIMAN, C. A; HANKINSON, S. E; SPIEGELMAN, D et al.Cancer research (Baltimore). 1999, Vol 59, Num 5, pp 1015-1020, issn 0008-5472Article

Cytochrome P450C17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrationsFEIGELSON, H. S; SHAMES, L. S; PIKE, M. C et al.Cancer research (Baltimore). 1998, Vol 58, Num 4, pp 585-587, issn 0008-5472Article

Acétate d'abiratérone (AA): comment prescrire l'abiratérone et à qui en 2014 ? = Abiraterone acetate (AA): Current guidelines of prescription of abirateroneBOISSIER, Émilie; LORIOT, Yohann; VIGNOT, Stéphane et al.Bulletin du cancer. 2014, Vol 101, Num 4, pp 388-393, issn 0007-4551, 6 p.Article

Imidazolylmethylbenzophenones as highly potent aromatase inhibitorsGOBBI, Silvia; CAVALLI, Andrea; NEGRI, Matthias et al.Journal of medicinal chemistry (Print). 2007, Vol 50, Num 15, pp 3420-3422, issn 0022-2623, 3 p.Article

Synthesis and evaluation of steroidal hydroxamic acids as inhibitors of p450 17 (17α-hydroxylase/C17-20-lyase)HAIDAR, Samer; KLEIN, Christian D. P; HARTMANN, Rolf W et al.Archiv der Pharmazie (Weinheim). 2001, Vol 334, Num 4, pp 138-140, issn 0365-6233Article

Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effectHABUCHI, Tomonori; ZHANG LIQING; KAMOTO, Toshiyuki et al.Cancer research (Baltimore). 2000, Vol 60, Num 20, pp 5710-5713, issn 0008-5472Article

CYP17 polymorphism in the groups of distinct breast cancer susceptibility : comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free womenKULIGINA, E. S; TOGO, A. V; SUSPITSIN, E. N et al.Cancer letters. 2000, Vol 156, Num 1, pp 45-50, issn 0304-3835Article

CYP17 and breast cancer risk : The polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1KRISTENSEN, V. N; HARALDSEN, E. K; ANDERSON, K. B et al.Cancer research (Baltimore). 1999, Vol 59, Num 12, pp 2825-2828, issn 0008-5472Article

Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)LUNN, R. M; BELL, D. A; MOHLER, J. L et al.Carcinogenesis (New York. Print). 1999, Vol 20, Num 9, pp 1727-1731, issn 0143-3334Article

CYP17 Inhibitors for Prostate Cancer Treatment : An UpdateMOREIRA, V. M; SALVADOR, J. A. R; VASAITIS, T. S et al.Current medicinal chemistry. 2008, Vol 15, Num 9, pp 868-899, issn 0929-8673, 32 p.Article

CYP19 (aromatase) : Exploring the scaffold flexibility for novel selective inhibitorsCASTELLANO, Sabrina; STEFANCICH, Giorgio; RAGNO, Rino et al.Bioorganic & medicinal chemistry. 2008, Vol 16, Num 18, pp 8349-8358, issn 0968-0896, 10 p.Article

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens : Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft modelHANDRATTA, Venkatesh D; VASAITIS, Tadas S; BRODIE, Angela M. H et al.Journal of medicinal chemistry (Print). 2005, Vol 48, Num 8, pp 2972-2984, issn 0022-2623, 13 p.Article

Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patientsROSSI, Laura; LEVERI, Michela; GRITTI, Chiara et al.Journal of hepatology. 2003, Vol 39, Num 4, pp 564-570, issn 0168-8278, 7 p.Article

Novel CYP17 inhibitors: Synthesis, biological evaluation, structure―activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenylsHILLE, Ulrike E; QINGZHONG HU; VOCK, Carsten et al.European journal of medicinal chemistry. 2009, Vol 44, Num 7, pp 2765-2775, issn 0223-5234, 11 p.Article

Page / 2